Rich Pharmaceuticals (RCHA) 10-Q 21 Nov 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Sep. 30, 2016	Nov. 03, 2016
Document And Entity Information
Entity Registrant Name	Rich Pharmaceuticals, Inc.
Entity Central Index Key	1,504,389
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		960,815,966
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,016

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Sep. 30, 2016	Mar. 31, 2016
Current Assets
Cash and equivalents
Prepaid expenses		2,800
Total Current Assets		2,800
Property and equipment, net	2,869	3,731
TOTAL ASSETS	2,869	6,531
Current Liabilities
Bank overdraft	2,148	2,948
Accounts payable	350,730	1,139,431
Accrued expenses	761,111	530,150
Due to related parties	39,100	76,913
Note payable	900,000
Convertible notes payable, net of debt discount	437,428	201,879
Derivative liabilities	270,531	446,912
Total Current Liabilities	2,761,048	2,398,233
Long-term Liabilities
Convertible notes payable, net of debt discount
Derivative liabilities
Total Long-term Liabilities
Total Liabilities	2,761,048	2,398,233
Stockholders Deficit
Preferred stock, $.001 par value, 10,000,000 shares authorized, 6,000,000 shares issued and outstanding, respectively	6,000	6,000
Common stock, $0.001 par value, 4,000,000,000 shares authorized, 640,739,418 and 216,364,262 shares issued and outstanding,	640,736	216,364
Additional paid-in capital	6,243,408	6,589,374
Accumulated deficit	(9,648,323)	(9,203,440)
Total Stockholders Deficit	(2,758,179)	(2,391,702)
TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT	$ 2,869	$ 6,531

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2016	Mar. 31, 2016	Sep. 06, 2013	Sep. 05, 2013
Statement of Financial Position [Abstract]
Common Stock, Par Value	$ .001	$ .001	$ 0.001	$ 0.001
Common Stock, Shares Authorized	4,000,000,000	4,000,000,000	375,030,000	900,000
Common Stock, Issued	640,739,418	216,364,262
Preferred Stock, Par Value	$ .001	$ .001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Issued	6,000,000	6,000,000

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
REVENUES
OPERATING EXPENSES
Consulting expenses	5,850		16,075	6,000
Office expenses	35,472	25,140	70,046	45,894
Depreciation expense	431	118	862	237
Wages and taxes	96,001	91,071	191,956	182,793
Professional fees	34,158	26,338	88,401	92,285
Regulatory fees	2,686	15,580	9,529	17,249
Research and development		2,000		9,000
Stock-based compensation		62,301		192,392
Travel, meals and entertainment	8,197	11,980	21,403	14,592
TOTAL OPERATING EXPENSES	182,795	234,528	398,272	560,442
LOSS FROM OPERATIONS	(182,795)	(234,528)	(398,272)	(560,442)
OTHER INCOME (EXPENSE)
Amortization of debt discount	(25,786)	(101,837)	(72,360)	(270,988)
Change in value of derivative liability	51,683	180,446	168,454	230,186
Derivative expense		(142,073)		(335,244)
Interest expense	(109,466)	(11,082)	(142,475)	(20,255)
Interest expense related party	(155)	(150)	(230)	(224)
Other Income Total	(83,724)	(74,696)	(46,611)	(396,525)
LOSS BEFORE PROVISION FOR INCOME TAXES	(266,519)	(309,224)	(444,883)	(956,967)
PROVISION FOR INCOME TAXES
NET LOSS	$ (266,519)	$ (309,224)	$ (444,883)	$ (956,697)
NET LOSS PER SHARE: BASIC AND DILUTED	$ 0	$ (0.01)	$ 0	$ (0.02)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED	461,006,135	35,569,186	398,719,073	56,827,068

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$ (266,519)	$ (309,224)	$ (444,883)	$ (956,697)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	431	118	862	237	$ 799
Amortization of debt discount	25,786	101,837	72,360	270,988
Change in value of derivative liability	(51,683)	(180,446)	(168,454)	(230,186)
Derivative expense		(142,073)		(335,244)
Interest converted into stock			5,416
Warrants issued for services				13,259
Stock-based compensation		62,301		192,392
Changes in operating assets and liabilities:
Decrease in prepaid expenses			2,800	5,485
Increase (decrease) in bank overdraft			(800)	484
Increase (decrease) in accounts payable			111,299	531
Increase in accrued expenses			230,961	137,398
Net Cash Used by Operating Activities			(190,438)	(231,136)
CASH FLOWS FROM FINANCING ACTIVITIES:
Loans received (repaid) from/to related parties			(37,812)	30,417
Proceeds from sale of common stock and warrants				50,873
Proceeds from issuance of convertible notes payable			228,250	133,954
Net Cash Provided by Financing Activities			190,438	215,244
Net Increase (Decrease) in Cash and Cash Equivalents				(15,892)
Cash and cash equivalents, beginning of period				15,892	15,892
Cash and cash equivalents, end of period
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid
Income taxes paid
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING INFORMATION:
Accounts payable converted into note payable			900,000
Original issue discounts recorded on notes payable				5,400
Debt discounts recorded on convertible notes payable				330,902
Debt/interest converted into common stock and contributed capital			$ 70,478	$ 308,451

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Nature of Business On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 5,312,925 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 5,002,554 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 2,625,210 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At September 30, 2016 and March 31, 2016 the Company had $- and $-, respectively, of unrestricted cash. Basis of Presentation The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These condensed financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2016, as filed with the U.S. Securities and Exchange Commission. Property and Equipment Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years. Long-Lived and Intangible Assets The Company accounts for long-lived and intangible assets in accordance with ASC Topic 360-10-05, “Accounting for the Impairment or Disposal of Long-Lived Assets.” ASC Topic 360-10-05 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value or disposable value. As of March 31, 2014, the Company fully impaired their intangible assets to $0. During the year ended March 31, 2015, the Company acquired another intangible asset from a related party and valued it at the cost of the intangible to the related party totaling $82,120. As of March 31, 2015, the Company fully impaired their intangible assets to $0. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at September 30, 2016 or March 31, 2016. As of September 30, 2016, the derivative liabilities were considered a level 2 item; see Note 8. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Revenue Recognition The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured. Research and Development The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes. Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 3,900,048 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 197,500 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 3,900,003 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $0.17; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $0.08 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.01 per share. Basic Loss Per Share The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. Recent Accounting Pronouncements The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Property and equipment

Property and equipment	6 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property and equipment	Property and equipment, recorded at cost, consisted of the following as of September 30, 2016 and March 31, 2016: September 30, 2016 March 31, 2016 Computer equipment & furniture $ 5,160 $ 5,160 Less: accumulated depreciation (2,291 ) (1,429 ) Property and equipment, net $ 2,869 $ 3,731 The useful life of the computer equipment and furniture is 3 years. Depreciation expense was $863 and $799 for the periods ended September 30, 2016 and March 31, 2016, respectively.

Intangible Assets

Intangible Assets	6 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 2,207,920 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0.

Accrued Expenses

Accrued Expenses	6 Months Ended
	Sep. 30, 2016
Payables and Accruals [Abstract]
Accrued Expenses	Accrued expenses consisted of the following as of September 30, 2016 and March 31, 2016: September 30, 2016 March 31, 2016 Wages and taxes $ 703,756 $ 514,713 Accrued interest 57,355 15,437 Total accrued expenses $ 761,111 $ 530,150

Related Party Debt and Transact

Related Party Debt and Transactions	6 Months Ended
	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Party Debt and Transactions	On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with its boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. During the year ended March 31, 2015 and 2014, the Company received loans from companies controlled by its new CEO or shareholders totaling $5,000 and $36,000, respectively. The loans are unsecured, non-interest bearing with no specific terms of repayment. The Company repaid all $41,000 of the loans during the year ended March 31, 2015. Also during the year ended March 31, 2015, the Company received a $6,000 loan from a shareholder. During the period ended September 30, 2016 the Company received an additional $6,280 from this related party. The loan is unsecured and bears 8% interest. There is a total due of $12,280 as of September 30, 2016. Interest accrued on the note as of September 30, 2016 was $597. The Company is in default on the balance of this note. During the period ending March 31, 2016, the Company received $22,200 in unsecured non-interest bearing loans from related parties and during the period ending September 30, 2016 received an additional $3,100, and has repaid $25,300 of these loans leaving a total due of $- as of September 30, 2016. These loans are deemed to be short-term and are payable at the discretion of the Company. On September 6, 2013, the Company entered into an Employment Agreement with our Chief Executive Officer, Chief Financial Officer, President and Secretary. The Employment Agreement provides for a term of two years; annual compensation of $275,000, a signing bonus of $68,750, and options to purchase up to 30,002 shares of common stock at an exercise price of $2.00 per share. The CEO earned $137,500 and $275,000 for the periods ended September 30, 2016 and March 31, 2016 (respectively) as a result of this agreement, these amounts contribute to the $531,362 and $395,630 of officer compensation which is included in accrued expenses, as of September 30, 2016 and March 31, 2016.

Note Payable

Note Payable	6 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Note Payable	On August 13, 2014, the Company issued a convertible note payable in the amount of $61,111 including an original issue discount of $5,500. The note has a one-time 12% interest charge and is due on August 14, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $61,111 of principal and $6,266 of interest into 1,403,700 shares of common stock leaving a remaining balance of $0. On September 18, 2014, the Company issued a convertible note payable in the amount of $64,500 including an original issue discount of $5,500. The note bears a one-time 12% interest charge and is due on September 18, 2015. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. However, if the market price during the 20 day trading period (mentioned above) is below $0.03, then the conversion factor will be reduced to 55%. During the year ended March 31, 2015, the note holder converted $10,000 of principal into 181,819 shares of common stock leaving a remaining balance of $54,500. During the period ending March 31, 2016 the note holder converted $54,500 in principal and $8,240 in accrued interest into 1,879,597 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On September 23, 2014, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on June 23, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $25,200 of the principle into 700,000 common shares leaving a remaining balance of $29,800. During the period ending March 31, 2016 the note holder converted $29,800 in principal and $2,158 in accrued interest into 864,672 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On October 6, 2014, the Company issued a convertible promissory note in the amount of $33,000. The note is due on July 6, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,000 in principal and $1,320 in accrued interest into 780,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016 . On November 6, 2014, the Company issued a convertible promissory note in the amount of $55,000. The note is due on May 6, 2015 and bears interest at 12% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 52.5% multiplied by lowest daily market price, for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date . On November 25, 2014, the Company issued a convertible promissory note in the amount of $43,000. The note is due on August 28, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $3,510 to increase the balance of the note and also converted $46,510 in principal into 5,290,270 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On December 16, 2014, the Company issued a convertible note payable in the amount of $33,333 including an original issue discount of $3,333. The note bears a one-time 12% interest charge and is due on December 16, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,333 in principal and $4000 in accrued interest into 5,047,167 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On January 9, 2015, the Company issued a convertible promissory note in the amount of $33,000. The note is due on October 13, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $16,500 to increase the balance of the note and also converted $49,500 in principal and $1,320 in interest into 8,470,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,020 in principal into 12,393,030 shares of common stock, and incurred a default fee of $27,000 leaving a remaining balance of $47,980. Interest accrued on this note as of September 30, 2016 is $5,579. The Company is in default on the balance of this note. On February 17, 2015, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $6,780. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $66,780 in principal and $3,148 in accrued interest into 8,854,031 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On February 25, 2015, the Company issued a convertible note payable in the amount of $27,778 including an original issue discount of $2,778. The note bears a one-time 12% interest charge and is due on February 25, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $27,778 in principal and $3,333 in accrued interest into 5,185,210 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and was originally due on December 9, 2015, with a revised due date of June 23, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $38,785 in principal and $5,135 in accrued interest into 57,733,852 shares of common stock. During the period ending June 30, 2016 the note holder converted $7,377 in principal and $422 in accrued interest into 46,484,586 shares of common stock leaving a remaining balance of $ 8,838. On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) days prior to the conversion date. During the period ending March 31, 2016 the note holder converted $10,929 in principal into 15,924,728 shares of common stock leaving a remaining balance of $18,751. The Company is in default on the balance of this note. On March 2, 2015, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible immediately at the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015 the note holder converted $56,402 of the principle into 1,215,551 common shares leaving a remaining balance of $1,898. During the period ending March 31, 2016 the note holder converted $1,898 in principal and $20 in accrued interest into 53,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On May 5, 2015, the Company issued a convertible note payable in the amount of $68,900 including an original issue discount of $3,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. . During the period ending March 31, 2016 the note holder converted $8,461 in principal and $566 in accrued interest into 18,135,267 shares of common stock. During the period ending September 30, 2016 the note holder converted $25,939 in principal and $2,675 in accrued interest into 224,358,188 shares of common stock leaving a remaining balance of $34,500. Accrued interest was $3,951 as of , 2016. On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. The Company incurred a default fee of $5,250, leaving a balance of $15,750 as of , 2016. The Company is in default on the balance of this note. On May 27, 2015, the Company issued a convertible note payable in the amount of $16,500. The note bears 8% interest rate and is due on May 28, 2016. The loan becomes convertible on May 27, 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $16,500 in principal and $344 in accrued interest into 2,591,323 shares of common stock leaving a remaining balance of $0. On August 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears 8% interest and is due on August 28, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending , 2016 the note holder converted $15,000 in principal and $939 in accrued interest into 87,032,383 shares of common stock leaving a remaining balance of $0. On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest and is due on June 4, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date. The loan balance as of , 2016 is $19,000, and On December 29, 2015, the Company issued a convertible note payable in the amount of $57,378. The note bears 8% interest rate and was originally due on December 30, 2016 , The loan becomes convertible on , 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $59,934 in principal and $1,222 in accrued interest into 35,927,887 shares of common stock, and incurred a default penalty of $4,165, leaving a remaining balance of $1,609. On January 22, 2016, the Company issued a convertible note payable in the amount of $60,500. The note bears 10% interest and is due on October 22, 2016. The loan becomes convertible on January 22, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued as of , 2016 is $4,177. On February 25, 2016, the Company issued a convertible note payable in the amount of $27,500. The note bears 8% interest rate and is due on February 25, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date.. , 2016 the note holder converted $16,745 in principal and $1,380 in interest into 66,500,000 shares of common stock leaving a remaining balance of $10,755. On March 24, 2016, the Company issued a convertible note payable in the amount of $7,500. The note bears 8% interest rate and is due on March 24, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. On May 25, 2016, the Company issued a convertible note payable in the amount of $30,000. The note bears 8% interest and is due on May 25, 2017. The loan becomes convertible 180 days after issuance or November 21, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. . On June 8, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $84,250. The note bears interest at the rate of 8% and must be repaid on or June 8, 2017. The note and any accrued interest may be converted into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. Interest accrued as of September 30, 2016 is $2,105. On June 23, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. Interest accrued as of June 30, 2016 is $1,215. On July 7, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $58,000. The note bears interest at the rate of 8% and must be repaid on or July 7, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017,

Convertible Note Payable

Convertible Note Payable	6 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Convertible Note Payable	On August 13, 2014, the Company issued a convertible note payable in the amount of $61,111 including an original issue discount of $5,500. The note has a one-time 12% interest charge and is due on August 14, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $61,111 of principal and $6,266 of interest into 1,403,700 shares of common stock leaving a remaining balance of $0. On September 18, 2014, the Company issued a convertible note payable in the amount of $64,500 including an original issue discount of $5,500. The note bears a one-time 12% interest charge and is due on September 18, 2015. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. However, if the market price during the 20 day trading period (mentioned above) is below $0.03, then the conversion factor will be reduced to 55%. During the year ended March 31, 2015, the note holder converted $10,000 of principal into 181,819 shares of common stock leaving a remaining balance of $54,500. During the period ending March 31, 2016 the note holder converted $54,500 in principal and $8,240 in accrued interest into 1,879,597 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On September 23, 2014, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on June 23, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $25,200 of the principle into 700,000 common shares leaving a remaining balance of $29,800. During the period ending March 31, 2016 the note holder converted $29,800 in principal and $2,158 in accrued interest into 864,672 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On October 6, 2014, the Company issued a convertible promissory note in the amount of $33,000. The note is due on July 6, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,000 in principal and $1,320 in accrued interest into 780,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016 . On November 6, 2014, the Company issued a convertible promissory note in the amount of $55,000. The note is due on May 6, 2015 and bears interest at 12% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 52.5% multiplied by lowest daily market price, for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date . On November 25, 2014, the Company issued a convertible promissory note in the amount of $43,000. The note is due on August 28, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $3,510 to increase the balance of the note and also converted $46,510 in principal into 5,290,270 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On December 16, 2014, the Company issued a convertible note payable in the amount of $33,333 including an original issue discount of $3,333. The note bears a one-time 12% interest charge and is due on December 16, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,333 in principal and $4000 in accrued interest into 5,047,167 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On January 9, 2015, the Company issued a convertible promissory note in the amount of $33,000. The note is due on October 13, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $16,500 to increase the balance of the note and also converted $49,500 in principal and $1,320 in interest into 8,470,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,020 in principal into 12,393,030 shares of common stock, and incurred a default fee of $27,000 leaving a remaining balance of $47,980. Interest accrued on this note as of September 30, 2016 is $5,579. The Company is in default on the balance of this note. On February 17, 2015, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $6,780. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $66,780 in principal and $3,148 in accrued interest into 8,854,031 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On February 25, 2015, the Company issued a convertible note payable in the amount of $27,778 including an original issue discount of $2,778. The note bears a one-time 12% interest charge and is due on February 25, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $27,778 in principal and $3,333 in accrued interest into 5,185,210 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and was originally due on December 9, 2015, with a revised due date of June 23, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $38,785 in principal and $5,135 in accrued interest into 57,733,852 shares of common stock. During the period ending June 30, 2016 the note holder converted $7,377 in principal and $422 in accrued interest into 46,484,586 shares of common stock leaving a remaining balance of $ 8,838. On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) days prior to the conversion date. During the period ending March 31, 2016 the note holder converted $10,929 in principal into 15,924,728 shares of common stock leaving a remaining balance of $18,751. The Company is in default on the balance of this note. On March 2, 2015, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible immediately at the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015 the note holder converted $56,402 of the principle into 1,215,551 common shares leaving a remaining balance of $1,898. During the period ending March 31, 2016 the note holder converted $1,898 in principal and $20 in accrued interest into 53,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On May 5, 2015, the Company issued a convertible note payable in the amount of $68,900 including an original issue discount of $3,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. . During the period ending March 31, 2016 the note holder converted $8,461 in principal and $566 in accrued interest into 18,135,267 shares of common stock. During the period ending September 30, 2016 the note holder converted $25,939 in principal and $2,675 in accrued interest into 224,358,188 shares of common stock leaving a remaining balance of $34,500. Accrued interest was $3,951 as of , 2016. On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. The Company incurred a default fee of $5,250, leaving a balance of $15,750 as of , 2016. The Company is in default on the balance of this note. On May 27, 2015, the Company issued a convertible note payable in the amount of $16,500. The note bears 8% interest rate and is due on May 28, 2016. The loan becomes convertible on May 27, 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $16,500 in principal and $344 in accrued interest into 2,591,323 shares of common stock leaving a remaining balance of $0. On August 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears 8% interest and is due on August 28, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending , 2016 the note holder converted $15,000 in principal and $939 in accrued interest into 87,032,383 shares of common stock leaving a remaining balance of $0. On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest and is due on June 4, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date. The loan balance as of , 2016 is $19,000, and On December 29, 2015, the Company issued a convertible note payable in the amount of $57,378. The note bears 8% interest rate and was originally due on December 30, 2016 , The loan becomes convertible on , 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $59,934 in principal and $1,222 in accrued interest into 35,927,887 shares of common stock, and incurred a default penalty of $4,165, leaving a remaining balance of $1,609. On January 22, 2016, the Company issued a convertible note payable in the amount of $60,500. The note bears 10% interest and is due on October 22, 2016. The loan becomes convertible on January 22, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued as of , 2016 is $4,177. On February 25, 2016, the Company issued a convertible note payable in the amount of $27,500. The note bears 8% interest rate and is due on February 25, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date.. , 2016 the note holder converted $16,745 in principal and $1,380 in interest into 66,500,000 shares of common stock leaving a remaining balance of $10,755. On March 24, 2016, the Company issued a convertible note payable in the amount of $7,500. The note bears 8% interest rate and is due on March 24, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. On May 25, 2016, the Company issued a convertible note payable in the amount of $30,000. The note bears 8% interest and is due on May 25, 2017. The loan becomes convertible 180 days after issuance or November 21, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. . On June 8, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $84,250. The note bears interest at the rate of 8% and must be repaid on or June 8, 2017. The note and any accrued interest may be converted into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. Interest accrued as of September 30, 2016 is $2,105. On June 23, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. Interest accrued as of June 30, 2016 is $1,215. On July 7, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $58,000. The note bears interest at the rate of 8% and must be repaid on or July 7, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017,

Derivative Liabilities

Derivative Liabilities	6 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Derivative Liabilities	In accordance with AC 815, the Company has bifurcated the conversion feature of their convertible notes and recorded a derivative liability on the date each note became convertible. The derivative liability was then revalued on each reporting date. As detailed in Note 7 (above) the Company has issued several convertible notes in varying amounts and terms, with the following loans becoming convertible during the periods ending September 30, 2016 and March 31, 2016: $33,000 noted dated October 6, 2014; $55,000 note dated November 6, 2014; $43,000 note dated November 25, 2014; $33,000 note dated January 9, 2015; $54,000 note dated February 5, 2015; $66,780 note dated February 17, 2015;$58,300 note dated March 2, 2015; $55,000 note dated March 9, 2015; $29,680 note dated March 26, 2015; $68,900 note dated May 5, 2015; $10,500 note dated May 6, 2015; $16,500 note dated May 27, 2015; $15,000 note dated August 28, 2015; $19,000 note dated September 4, 2015; $55,000 note dated December 29, 2015; $60,500 note dated January 22, 2016; $27,500 note dated February 25, 2016; $7,500 note dated March 24, 2016. ASC 815 requires Company management to assess the fair market value of certain derivatives at each reporting period and recognize any change in the fair market value as another income or expense item. The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with the above convertible debt. During the period ended September 30, 2016, the Company recorded a total change in the fair market value of the derivative liabilities of $168,454. The Company uses the Black-Scholes option pricing model to value the derivative liability upon the initial conversion date and at each reporting period. Included in the model to value the derivative liabilities of the above loans are the following assumptions: stock price at valuation date of $0.0002, exercise price of $0.0001 - $0.000116, dividend yield of zero, years to maturity of 0.060270 – .728770, a risk free rate of 0.29% - 0.59%, and annualized volatility of 284% - 379%. The above loans were all discounted in full with the exception of the March 2, 2015 loan which had a debt discount of $46,370, the May 5, 2015 loan which had an initial debt discount of $41,222, and the May 27, 2015 loan which had an initial debt discount of $15,000. Based on the valuations on the initial valuation dates for the period ending September 30, 2016, the Company recognized debt discounts related to the conversion features totaling $- and a derivative expense of $- related to the excess value of the derivative liabilities. Once the loans are fully converted, the remaining derivative liability is reclassified to equity as additional paid-in capital. As of September 30, 2016, unamortized debt discount, including original issue discounts totaled $16,005. The derivative liabilities totaled $270,531 as of September 30, 2016, of which $- related to long-term debt.

Equity Transactions

Equity Transactions	6 Months Ended
	Sep. 30, 2016
Equity Transactions
Equity Transactions	The Company has 4,000,000,000 common shares authorized with a par value of $ 0.001 per share. The Company has 10,000,000 preferred shares authorized with a par value of $ 0.001 per share. On July 18, 2013, the Company designated, from the 10,000,000 authorized shares of preferred stock, 6,000,000 shares of Series “A” Preferred Stock. The Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company granted 6,000,000 Series “A” Preferred shares and 827,670 common shares for the intellectual property. The common and preferred shares were valued at a total of $123,973. On July 19, 2013, our new officer/director agreed to cancel 5,002,554 common shares and returned them to treasury. Certain other shareholders also agreed to cancel 2,625,210 common shares. On September 5, 2013, the Company increased the authorized common shares from 900,000 to 375,030,000. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. On October 29, 2013, the Company granted 2,500 units at $30.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $50.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On December 11, 2013, the Company granted 2,500 units at $30.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $50.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On June 9, 2015, the Company issued 900,000 units at $0.02 per unit. Each unit consisted of one common stock warrant with an exercise price of $0.02 and a five year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below On December 15, 2015, the Company issued 4,000,000 units at $0.01 per unit. Each unit consisted of one common stock warrant with an exercise price of $0.01 and a five year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model. Date June 9, 2015 Dec 15,2015 Warrants 900,000 4,000,000 Stock price on grant date $0.02 $0.01 Exercise price $0.02 $0.01 Expected life 5 year 5 year Volatility 98% 98% Risk-free rate 1.74% 1.71% Calculated value $13,259 $29,612 Fair value allocation of proceeds $13,259 $29,612 The following is a summary of the warrant activity for the period March 31, 2016 to September 30, 2016: Number of warrants Weighted average exercise price Outstanding, March 31, 2016 4,930,666 $ 0.192 Granted $ — Exercised — — Outstanding, September 30, 2016 4,930,666 $ 0.192 On April 22, 2015, the Company sold 100,381 shares of common stock for $5,405 in cash, which was paid directly to a vendor for accounts payable. On June 25, 2015, the Company sold 1,542,455 shares of common stock for $10,797 in cash, of which $3,750 was paid directly to professionals in connection with the expenses of that sale, and $7,047 was retained by the Company. On July 7, 2015, the Company sold 1,619,423 shares of common stock for $11,336 in cash, of which $3,750 was paid directly to a vendor for professional services. On July 15, 2015, the Company sold 1,439,282 shares of common stock for $10,075 in cash. On October 27, 2015, the Company sold 1,648,840 shares of common stock for $11,542 in cash. During the periods ended September 30, 2016 and March 31, 2016, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest: On February 8, 2016, the Company approved a change in the authorized shares of common stock to 4,000,000,000 shares. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option, whichever can be more clearly determined. During the year ended March 31, 2014, the Company granted 475,033 stock options to officers, directors, employees and consultants. During the year ended March 31, 2015, the Company granted 197,500 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 3,900,003 stock options to officers, directors, employees and consultants The options have been re-priced twice as follows: (1) Effective January 12, 2015, the Company approved the re-pricing of all 672,533 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $1.91984 per share and $30.0 per share, to $0.17 per share which was the closing price of the Company’s common stock on January 9, 2015. All of the other terms of the options remained unchanged. Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $16,650 411,111 $0.04050 April 6, 2015 $10,000 209,644 $0.04770 April 8, 2015 $15,309 453,561 $0.03375 April 8, 2015 $20,001 454,545 $0.04400 April 9, 2015 $14,320 325,455 $0.04400 April 14, 2015 $10,000 236,967 $0.04220 April 16, 2015 $1,918 53,000 $0.03619 April 21, 2015 $10,000 259,740 $0.03850 April 29, 2015 $15,000 389,610 $0.03850 May 4, 2015 $5,083 131,464 $0.03866 May 12, 2015 $28,456 903,380 $0.03150 May 20, 2015 $20,199 947,645 $0.02131 May 20, 015 $17,240 783,636 $0.02200 May 27, 2015 $13,568 701,801 $0.01933 May 29, 2015 $15,000 882,353 $0.01700 June 11, 2015 $9,897 942,609 $0.01050 June 16, 2015 $14,100 1,175,000 $0.01200 June 16, 2015 $13,565 1,130,417 $0.01200 June 22, 2015 $7,415 1,235,833 $0.00600 June 22, 2015 $14,384 2,479,924 $0.00580 June 23, 2015 $7,752 1,292,000 $0.00600 September 16, 2015 $7,974 1,772,033 $0.00450 September 28, 2015 $10,000 1,666,667 $0.00600 September 29, 2015 $10,620 1,770,000 $0.00600 October 7, 2015 $2,250 375,000 $0.00600 October 7, 2015 $8,400 1,400,000 $0.00600 October 19, 2015 $9,720 1,620,000 $0.00600 November 2, 2015 $4,424 1,966,124 $0.00225 November 23, 2015 $10,000 1,666,667 $0.00600 November 30, 2015 $16,844 2,591,323 $0.00650 December 9, 2015 $1,746 775,991 $0.00225 December 17, 2015 $5,332 919,319 $0.00580 December 28, 2015 $1,341 596,200 $0.00225 December 28, 2015 $17,700 2,950,000 $0.00600 December 28, 2015 $14,305 2,384,167 $0.00600 December 28, 2015 $14,963 2,579,916 $0.00580 December 29, 2015 $8,395 1,399,167 $0.00600 December 29, 2015 $7,670 1,278,333 $0.00600 December 30, 2015 $6,651 2,956,248 $0.00225 January 1, 2016 $28,500 4,384,615 $0.00650 January 4, 2016 $19,339 3,223,213 $0.00600 January 5, 2016 $8,107 3,603,227 $0.00225 January 6, 2016 $16,070 2,678,333 $0.00600 January 6, 2016 $16,597 2,861,607 $0.00580 February 16 ,2016 $1,424 4,220,400 $0.00034 February 17, 2016 $12,800 8,443,272 $0.00152 February 23, 2016 $4,640 4,218,182 $0.00110 February 23, 2016 $3,086 4,200,871 $0.00073 February 24, 2016 $1,492 4,419,970 $0.00034 February 25, 2016 $3,000 2,638,987 $0.00114 February 25, 2016 $4,640 4,218,182 $0.00110 March 1, 2016 $1,313 5,834,458 $0.00022 March 2, 2016 $4,600 5,831,643 $0.00079 March 2, 2016 $1,650 2,586,410 $0.00064 March 2, 2016 $9,332 11,650,000 $0.00080 March 7, 2016 $2,799 6,546,292 $0.00043 March 11, 2016 $1,924 4,147,500 $0.00046 March 14, 2016 $2,245 7,125,777 $0.00032 March 15, 2016 $3,329 7,454,098 $0.00045 March 15, 2016 $5,210 11,450,000 $0.00046 March 22, 2016 $2,419 8,957,888 $0.00027 March 22, 2016 $2,367 7,200,486 $0.00033 March 22, 2016 $5,315 11,682,000 $0.00046 March 28, 2016 $1,986 8,958,779 $0.00022 March 31, 2016 Total $602,376 194,603,040 Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2016 $2,197 9,766,311 $0.000225 April 4, 2016 $4,847 17,250,000 $0.000281 April 7, 2016 $1,750 9,722,222 $0.000180 April 14, 2016 $4,158 19,250,000 $0.000216 April 15, 2016 $1,318 9,766,222 $0.000135 April 26, 2016 $1,705 12,629,776 $0.000135 May 4, 2016 $2,067 9,718,025 $0.000213 May 31, 2016 $ 828 4,600,055 $0.000180 June 2, 2016 $9,120 30,000,000 $0.000304 June 2, 2016 $4,401 29,340,333 $0.000150 June 14, 2016 $5,847 29,235,900 $.0.000200 June 17,2016 $5,691 28,456,150 $0.000200 June 29, 2016 $6,580 21,270,355 $0.000309 August 23, 2016 $2,567 22,129,741 $0.000116 August 29, 2016 $2,570 22,156,120 $0.000116 September 6, 2016 $2,547 21,952,672 $0.000116 September 20, 2016 $2,443 25,267,655 $0.000097 September 26, 2016 $2,946 25,393,448 $0.000116 September 28, 2016 $2,947 25,403,448 $0.000116 September 30, 2016 $3,949 51,066,724 $0.000077 September 30, 2016 Total $70,478 424,375,157 (2) Effective April 6, 2015, the Company approved the re-pricing of all 2,712,535 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $.08 per share and $0.17 per share, to $0.08 per share which was the closing price of the Company’s common stock on April 6, 2015. All of the other terms of the options remained unchanged. (3) Effective August 4, 2015, the Company approved the re-pricing of all 3,712,535 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $.08 per share and $0.02 per share, to $0.02 per share which was the closing price of the Company’s common stock on August 4, 2015. All of the other terms of the options remained unchanged. The Company revalued all existing options on January 12, 2015 and again on April 6, 2015, and again on August 4, 2015 using the Black-Scholes option pricing model using the initial terms of the options and the modified terms of the options. The difference in the valuations was recorded as additional expense. The re-pricing of the options resulted in the recognition of an additional $50,448 on January 9, 2015 and an additional $9,316 on April 6, 2015, and an additional $47,463 on August 4, 2015 in related stock based compensation expense for those periods. The following is a summary of the inputs used to determine the value of the options using the Black-Scholes option pricing model. Date April 6, 2015 June 9, 2015 December 15, 2015 Options 2,040,003 1,000,000 860,000 Stock price grant date $0.08 $0.02 $0.01 Initial Exercise price $0.08 $0.02 $0.01 Modified Exercise price $0.01 $0.01 $0.01 Expected life 5.0 5.0 5.0 Volatility 99% 99% 84% Risk-free rate 1.31% 1.74% 1.70% Calculated value $120,778 $14,838 $5,736 Modified value $151,221 $16,347 $5,736 The following is a summary of the option activity for the period March 31, 2015 through September 30, 2016: Number of options Weighted average exercise price Outstanding, March 31, 2015 672,533 $0.01 Granted 3,900,003 $0.01 Exercised - - Expired - - Outstanding, September 30, 2016 4,572,536 $0.01

Commitments and Contigencies

Commitments and Contigencies	6 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Commitments and Contingencies	The Company leases office space on a verbal month-to-month agreement. Monthly rent is approximately $2,800. On July 8, 2016, the Company engaged a foreign based company to evaluate the safety and efficacy of RP-323 over a 27 month period. The contract stipulates a commitment of $193,255 with additional fees for pass-through expenses. The inventor of the intellectual property which was assigned to Rich Pharmaceuticals, Inc. in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “District Court”). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (the “Litigation”). The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. As previously disclosed on January 4, 2016, the Litigation has been settled through a confidential mediation process supervised by the Federal Court and the Litigation has been dismissed with prejudice by the Federal Court. The Company incurred substantial fees in defending the litigation.

Liquidity and Going Concern

Liquidity and Going Concern	6 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	The Company has a working capital deficit, has not yet received revenues from sales of products or services, and has incurred losses since inception. These factors create substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

Subsequent Events

Subsequent Events	6 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Subsequent Events	On October 7, 2016, the Company converted $3,035 in principle and $346 in interest on a convertible note payable into 58,291,551 shares of common stock. On October 14, 2016, the Company converted $3,030 in principle and $350 in interest on a convertible note payable into 58,275,689 shares of common stock. On October 21, 2016, the Company converted $3,033 in principle and $355 in interest on a convertible note payable into 58,355,689 shares of common stock. On October 26, 2016, the Company converted $3,025 in principle and $358 in interest on a convertible note payable into 58,316,551 shares of common stock. On October 20, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $58,000. The note bears interest at the rate of 8% and must be repaid on or October 20, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, On October 28, 2016, the Company issued an 8% convertible redeemable promissory note in the principal amount of $32,000. The note must be repaid on or before October 20, 2017. The note and any accrued interest may be converted by the lender into shares of Company common stock 180 days after issuance or April 26, 2017, at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. On November 7, 2016, the Company converted $5,015 of debt and interest on a convertible note payable into 86,472,931 shares of common stock. In accordance with ASC 855-10, the Company has analyzed its operations subsequent to September 30, 2016 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described above.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Nature of Business	On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 5,312,925 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 5,002,554 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 2,625,210 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.
Cash and Cash Equivalents	The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At September 30, 2016 and March 31, 2016 the Company had $- and $-, respectively, of unrestricted cash.
Basis of Presentation	The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These condensed financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2016, as filed with the U.S. Securities and Exchange Commission.
Property and Equipment	Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years.
Long-Lived and Intangible Assets	On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 2,207,920 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0.
Fair Value of Financial Instruments	The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at September 30, 2016 or March 31, 2016. As of September 30, 2016, the derivative liabilities were considered a level 2 item; see Note 8.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Income Taxes	Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.
Revenue Recognition	The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured.
Research and Development	The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes.
Stock-Based Compensation	Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 3,900,048 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 197,500 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 3,900,003 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $0.17; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $0.08 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.01 per share.
Basic loss per share	The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity.
Recent Accounting Pronouncements	The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Property and equipment (Tables)

Property and equipment (Tables)	6 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	September 30, 2016 March 31, 2016 Computer equipment & furniture $ 5,160 $ 5,160 Less: accumulated depreciation (2,291 ) (1,429 ) Property and equipment, net $ 2,869 $ 3,731

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Sep. 30, 2016
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	September 30, 2016 March 31, 2016 Wages and taxes $ 703,756 $ 514,713 Accrued interest 57,355 15,437 Total accrued expenses $ 761,111 $ 530,150

Equity Transactions (Tables)

Equity Transactions (Tables)	6 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Schedule of Value of Warrants	Date June 9, 2015 Dec 15,2015 Warrants 900,000 4,000,000 Stock price on grant date $0.02 $0.01 Exercise price $0.02 $0.01 Expected life 5 year 5 year Volatility 98% 98% Risk-free rate 1.74% 1.71% Calculated value $13,259 $29,612 Fair value allocation of proceeds $13,259 $29,612
Schedule of Warrant Activity	Number of warrants Weighted average exercise price Outstanding, March 31, 2016 4,930,666 $ 0.192 Granted $ — Exercised — — Outstanding, September 30, 2016 4,930,666 $ 0.192
Schedule of Conversions of Common Stock	Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $16,650 411,111 $0.04050 April 6, 2015 $10,000 209,644 $0.04770 April 8, 2015 $15,309 453,561 $0.03375 April 8, 2015 $20,001 454,545 $0.04400 April 9, 2015 $14,320 325,455 $0.04400 April 14, 2015 $10,000 236,967 $0.04220 April 16, 2015 $1,918 53,000 $0.03619 April 21, 2015 $10,000 259,740 $0.03850 April 29, 2015 $15,000 389,610 $0.03850 May 4, 2015 $5,083 131,464 $0.03866 May 12, 2015 $28,456 903,380 $0.03150 May 20, 2015 $20,199 947,645 $0.02131 May 20, 015 $17,240 783,636 $0.02200 May 27, 2015 $13,568 701,801 $0.01933 May 29, 2015 $15,000 882,353 $0.01700 June 11, 2015 $9,897 942,609 $0.01050 June 16, 2015 $14,100 1,175,000 $0.01200 June 16, 2015 $13,565 1,130,417 $0.01200 June 22, 2015 $7,415 1,235,833 $0.00600 June 22, 2015 $14,384 2,479,924 $0.00580 June 23, 2015 $7,752 1,292,000 $0.00600 September 16, 2015 $7,974 1,772,033 $0.00450 September 28, 2015 $10,000 1,666,667 $0.00600 September 29, 2015 $10,620 1,770,000 $0.00600 October 7, 2015 $2,250 375,000 $0.00600 October 7, 2015 $8,400 1,400,000 $0.00600 October 19, 2015 $9,720 1,620,000 $0.00600 November 2, 2015 $4,424 1,966,124 $0.00225 November 23, 2015 $10,000 1,666,667 $0.00600 November 30, 2015 $16,844 2,591,323 $0.00650 December 9, 2015 $1,746 775,991 $0.00225 December 17, 2015 $5,332 919,319 $0.00580 December 28, 2015 $1,341 596,200 $0.00225 December 28, 2015 $17,700 2,950,000 $0.00600 December 28, 2015 $14,305 2,384,167 $0.00600 December 28, 2015 $14,963 2,579,916 $0.00580 December 29, 2015 $8,395 1,399,167 $0.00600 December 29, 2015 $7,670 1,278,333 $0.00600 December 30, 2015 $6,651 2,956,248 $0.00225 January 1, 2016 $28,500 4,384,615 $0.00650 January 4, 2016 $19,339 3,223,213 $0.00600 January 5, 2016 $8,107 3,603,227 $0.00225 January 6, 2016 $16,070 2,678,333 $0.00600 January 6, 2016 $16,597 2,861,607 $0.00580 February 16 ,2016 $1,424 4,220,400 $0.00034 February 17, 2016 $12,800 8,443,272 $0.00152 February 23, 2016 $4,640 4,218,182 $0.00110 February 23, 2016 $3,086 4,200,871 $0.00073 February 24, 2016 $1,492 4,419,970 $0.00034 February 25, 2016 $3,000 2,638,987 $0.00114 February 25, 2016 $4,640 4,218,182 $0.00110 March 1, 2016 $1,313 5,834,458 $0.00022 March 2, 2016 $4,600 5,831,643 $0.00079 March 2, 2016 $1,650 2,586,410 $0.00064 March 2, 2016 $9,332 11,650,000 $0.00080 March 7, 2016 $2,799 6,546,292 $0.00043 March 11, 2016 $1,924 4,147,500 $0.00046 March 14, 2016 $2,245 7,125,777 $0.00032 March 15, 2016 $3,329 7,454,098 $0.00045 March 15, 2016 $5,210 11,450,000 $0.00046 March 22, 2016 $2,419 8,957,888 $0.00027 March 22, 2016 $2,367 7,200,486 $0.00033 March 22, 2016 $5,315 11,682,000 $0.00046 March 28, 2016 $1,986 8,958,779 $0.00022 March 31, 2016 Total $602,376 194,603,040 Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2016 $2,197 9,766,311 $0.000225 April 4, 2016 $4,847 17,250,000 $0.000281 April 7, 2016 $1,750 9,722,222 $0.000180 April 14, 2016 $4,158 19,250,000 $0.000216 April 15, 2016 $1,318 9,766,222 $0.000135 April 26, 2016 $1,705 12,629,776 $0.000135 May 4, 2016 $2,067 9,718,025 $0.000213 May 31, 2016 $ 828 4,600,055 $0.000180 June 2, 2016 $9,120 30,000,000 $0.000304 June 2, 2016 $4,401 29,340,333 $0.000150 June 14, 2016 $5,847 29,235,900 $.0.000200 June 17,2016 $5,691 28,456,150 $0.000200 June 29, 2016 $6,580 21,270,355 $0.000309 August 23, 2016 $2,567 22,129,741 $0.000116 August 29, 2016 $2,570 22,156,120 $0.000116 September 6, 2016 $2,547 21,952,672 $0.000116 September 20, 2016 $2,443 25,267,655 $0.000097 September 26, 2016 $2,946 25,393,448 $0.000116 September 28, 2016 $2,947 25,403,448 $0.000116 September 30, 2016 $3,949 51,066,724 $0.000077 September 30, 2016 Total $70,478 424,375,157
Schedule of Value of Options	Date April 6, 2015 June 9, 2015 December 15, 2015 Options 2,040,003 1,000,000 860,000 Stock price grant date $0.08 $0.02 $0.01 Initial Exercise price $0.08 $0.02 $0.01 Modified Exercise price $0.01 $0.01 $0.01 Expected life 5.0 5.0 5.0 Volatility 99% 99% 84% Risk-free rate 1.31% 1.74% 1.70% Calculated value $120,778 $14,838 $5,736 Modified value $151,221 $16,347 $5,736
Schedule of Option Activity	Number of options Weighted average exercise price Outstanding, March 31, 2015 672,533 $0.01 Granted 3,900,003 $0.01 Exercised - - Expired - - Outstanding, September 30, 2016 4,572,536 $0.01

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Details Narrative)	3 Months Ended	6 Months Ended		12 Months Ended
	Sep. 30, 2015shares	Sep. 30, 2016USD ($)$ / sharesshares	Sep. 30, 2015shares	Mar. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2015shares	Mar. 31, 2014shares	Mar. 31, 2013	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares
Date Of Incorporation		Aug. 9, 2010
Common Stock, shares issued	14,690
Cancellation of loans | $
Common Stock, Shares Authorized		4,000,000,000		4,000,000,000				375,030,000	900,000
Common Stock, Par Value | $ / shares		$ .001		$ .001				$ 0.001	$ 0.001
Stock split ratio		0.01					4.1671
Cash and cash equivalent | $
Intangible assets | $		0
Impairment of intangible asset | $		$ 82,120
Reserved common shares		3,900,048
Stock options granted		3,900,003		197,500
Computer equipment		3 years
Options granted, number of shares			3,900,003	3,900,003	197,500	475,033
Options, exercise price | $ / shares		$ 0.001
Sale Agmt
Date of Agreement		Jul. 19, 2013
Cancellation of loans | $		$ 28,818
Shares sold by former officers		5,312,925
Shares returned to treasury		5,002,554
Shares agreed to cancel		2,625,210
Asset Assign Agmt
Date of Agreement		Jul. 18, 2013
Common Stock, shares issued		827,670
Series A Preferred Stock, shares issued		6,000,000
Stock Value | $		$ 123,973
Termination of agreement | $		20,000
Additional cash required | $		$ 2,000,000

Property and equipment - Schedu

Property and equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2016	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Computer equipment	$ 5,160	$ 5,160
Less: accumulated depreciation	(2,291)	(1,429)
Property and equipment, net	$ 2,869	$ 3,731

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016
Property And Equipment Details Narrative
Depreciation expense	$ 431	$ 118	$ 862	$ 237	$ 799
Computer equipment			3 years

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Sep. 30, 2015	Sep. 30, 2016
Common Stock, shares issued	14,690
Impairment of intangible asset		$ 82,120
Asset Assign Agmt
Date of Agreement		Jul. 18, 2013
Common Stock, shares issued		827,670
Series A Preferred Stock, shares issued		6,000,000
Stock Value		$ 123,973
Asset Assign Agmt #2
Date of Agreement		Oct. 6, 2014
Common Stock, shares issued		2,207,920
Common stock, value		$ 7,904,355
Impaired Assets		0
Impairment of intangible asset		$ 82,120

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Sep. 30, 2016	Mar. 31, 2016
Payables and Accruals [Abstract]
Wages and taxes	$ 703,756	$ 514,713
Accrued interest	57,355	15,437
Total accrued expenses	$ 761,111	$ 530,150

Related Party Debt and Transa27

Related Party Debt and Transactions (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2016
Cancellation of loans
Due to related parties	$ 39,100		39,100				$ 76,913
Loans and interest received (repaid) from/to related parties			(37,812)	$ 30,417
Interest expense, related party	(155)	$ (150)	(230)	$ (224)
Accrued expenses	$ 761,111		$ 761,111				530,150
Sale Agmt
Date of Agreement			Jul. 19, 2013
Cancellation of loans			$ 28,818
CEO
Loan from related party					$ 5,000	$ 36,000
Repayment of loans to related parties					41,000
SH Loan #1
Loan from related party					$ 6,000
Interest Rate					8.00%
SH Loan #2
Loan from related party			$ 6,280
Interest Rate	8.00%		8.00%
Interest expense, related party			$ (597)
Related Party Loans
Repayment of loans to related parties			25,300
Accrued expenses	$ 3,100		3,100				$ 22,200
Accrued expenses, balance due
Employment Agmt
Date of Agreement			Sep. 6, 2013
Term of Agreement			2 years
Annual Compensation			$ 275,000
Options to purchase			30,002
Options to purchase, exercise price			$ 0.02
Bonus			$ 68,750
Earnings			137,500		$ 275,000
Accrued Earnings			$ 531,362		$ 395,630

Note Payable (Details Narrative

Note Payable (Details Narrative) - Note Payable #1	6 Months Ended
	Sep. 30, 2016USD ($)
Date of Agreement	Aug. 13, 2014
Convertible Note	$ 900,000
Interest Rate	10.00%
Due Date	Aug. 1, 2017
Interest Accrued	$ 30,082

Convertible Note Payable (Detai

Convertible Note Payable (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Debt Instrument, Converted Amount			$ 70,478	$ 308,451
Debt Instrument, Interest Accrued, Converted Amount			5,416
Common Stock, shares issued		14,690
Convertible Prom Note #6
Date of Agreement						Aug. 13, 2014
Convertible Note						$ 61,111
Interest Rate						12.00%
Due Date						Aug. 14, 2016
Interest Accrued			0			$ 1,067
Convertible Note, Balance						0
Original Issue Discount						5,500
Debt Instrument, Converted Amount						61,111
Debt Instrument, Interest Accrued, Converted Amount			$ 1,067			$ 6,266
Common Stock, shares issued			177,836			1,403,700
Convertible Prom Note #8
Date of Agreement						Sep. 18, 2014
Convertible Note						$ 64,500
Interest Rate						12.00%
Due Date						Sep. 18, 2015
Interest Accrued			$ 0			$ 8,240
Convertible Note, Balance			0			54,500
Original Issue Discount						5,500
Debt Instrument, Converted Amount			54,500			$ 10,000
Debt Instrument, Interest Accrued, Converted Amount			$ 8,240
Common Stock, shares issued			1,879,597			181,819
Convertible Prom Note #9
Date of Agreement						Sep. 23, 2014
Convertible Note						$ 55,000
Interest Rate						8.00%
Due Date						Jun. 23, 2015
Interest Accrued			$ 0			$ 2,158
Convertible Note, Balance			0			29,800
Debt Instrument, Converted Amount			29,800			$ 25,200
Debt Instrument, Interest Accrued, Converted Amount			$ 2,158
Common Stock, shares issued			864,672			700,000
Convertible Prom Note #10
Date of Agreement			Oct. 6, 2014
Convertible Note			$ 33,000
Interest Rate			8.00%
Due Date			Jul. 6, 2015
Interest Accrued			$ 0
Convertible Note, Balance			0
Debt Instrument, Converted Amount			33,000
Debt Instrument, Interest Accrued, Converted Amount			$ 1,320
Common Stock, shares issued			780,000
Convertible Prom Note #11
Date of Agreement			Nov. 6, 2014
Convertible Note			$ 55,000
Interest Rate			12.00%
Due Date			May 6, 2015
Interest Accrued			$ 0
Convertible Note, Balance			0
Debt Instrument, Converted Amount			55,000
Debt Instrument, Interest Accrued, Converted Amount			$ 3,553
Common Stock, shares issued			2,813,634
Convertible Prom Note #12
Date of Agreement			Nov. 25, 2014
Convertible Note			$ 43,000
Interest Rate			8.00%
Due Date			Aug. 28, 2015
Interest Accrued			$ 0
Convertible Note, Balance			0
Debt Instrument, Converted Amount			$ 46,510
Common Stock, shares issued			5,290,270
Fee			Default
Fee Amount					$ 3,510
Convertible Prom Note #13
Date of Agreement			Dec. 16, 2014
Convertible Note			$ 33,333
Interest Rate			12.00%
Due Date			Dec. 16, 2016
Interest Accrued			$ 0
Convertible Note, Balance			0
Original Issue Discount			3,333
Debt Instrument, Converted Amount			33,333
Debt Instrument, Interest Accrued, Converted Amount			$ 4,000
Common Stock, shares issued			5,047,167
Convertible Prom Note #14
Date of Agreement			Jan. 9, 2015
Convertible Note			$ 33,000
Interest Rate			8.00%
Due Date			Oct. 13, 2015
Interest Accrued			$ 0
Convertible Note, Balance			0
Debt Instrument, Interest Accrued, Converted Amount			$ 1,320
Common Stock, shares issued			8,470,000
Fee			Default
Fee Amount					16,500
Convertible Prom Note #15
Date of Agreement			Feb. 5, 2015
Convertible Note			$ 54,000
Interest Rate			8.00%
Due Date			Nov. 9, 2015
Interest Accrued			$ 5,579
Convertible Note, Balance			$ 47,980
Common Stock, shares issued			12,393,030
Fee			Default
Fee Amount					$ 27,000
Convertible Prom Note #16
Date of Agreement			Feb. 17, 2015
Convertible Note			$ 66,780
Interest Rate			8.00%
Due Date			Aug. 14, 2015
Interest Accrued			$ 0
Convertible Note, Balance			0
Original Issue Discount			6,780
Debt Instrument, Converted Amount			66,780
Debt Instrument, Interest Accrued, Converted Amount			$ 3,148
Common Stock, shares issued			8,854,031
Convertible Prom Note #17
Date of Agreement			Feb. 25, 2015
Convertible Note			$ 27,778
Interest Rate			12.00%
Due Date			Feb. 25, 2017
Interest Accrued			$ 0
Convertible Note, Balance			0
Debt Instrument, Converted Amount			27,778
Debt Instrument, Interest Accrued, Converted Amount			$ 3,333
Common Stock, shares issued			5,185,210
Convertible Prom Note #18
Date of Agreement					Mar. 9, 2015
Convertible Note					$ 55,000
Interest Rate					8.00%
Due Date	Jun. 23, 2017				Dec. 9, 2015
Interest Accrued	$ 0		$ 178		$ 0
Convertible Note, Balance	8,838				16,215
Debt Instrument, Converted Amount	7,377				38,785
Debt Instrument, Interest Accrued, Converted Amount	$ 422				$ 5,135
Common Stock, shares issued	46,484,586				57,733,852
Convertible Prom Note #19
Date of Agreement					Mar. 26, 2015
Convertible Note					$ 29,680
Interest Rate					8.00%
Due Date					Mar. 23, 2016
Interest Accrued			4,520		$ 2,577
Convertible Note, Balance					18,751
Original Issue Discount					1,680
Debt Instrument, Converted Amount					$ 10,929
Common Stock, shares issued					15,924,728
Convertible Prom Note #20
Date of Agreement						Mar. 2, 2015
Convertible Note						$ 58,300
Interest Rate						8.00%
Due Date						Aug. 14, 2015
Interest Accrued			0
Convertible Note, Balance			0			$ 1,898
Original Issue Discount						3,300
Debt Instrument, Converted Amount			1,898			$ 56,402
Debt Instrument, Interest Accrued, Converted Amount			$ 20
Common Stock, shares issued			53,000			1,215,551
Convertible Prom Note #21
Date of Agreement					May 5, 2015
Convertible Note					$ 68,900
Interest Rate					8.00%
Due Date					May 5, 2016
Interest Accrued			$ 3,951		$ 4,387
Convertible Note, Balance			34,500		60,439
Original Issue Discount					3,900
Original Issue Discount, unamortized					325
Debt Instrument, Converted Amount			25,939		8,461
Debt Instrument, Interest Accrued, Converted Amount			$ 2,675		$ 566
Common Stock, shares issued			224,358,188		18,135,267
Convertible Prom Note #22
Date of Agreement					May 6, 2015
Convertible Note					$ 10,500
Interest Rate					8.00%
Due Date					Feb. 8, 2016
Interest Accrued			$ 1,451		$ 1,133
Convertible Note, Balance					$ 15,750
Fee					Default
Fee Amount			$ 5,250
Convertible Prom Note #23
Date of Agreement			May 27, 2015
Convertible Note			$ 16,500
Interest Rate			8.00%
Due Date			May 28, 2016
Interest Accrued			$ 0
Convertible Note, Balance			0
Debt Instrument, Converted Amount			16,500
Debt Instrument, Interest Accrued, Converted Amount			$ 344
Common Stock, shares issued			2,591,323
Convertible Prom Note #24
Date of Agreement			Aug. 28, 2015
Convertible Note			$ 15,000
Interest Rate			8.00%
Due Date			Aug. 28, 2016
Interest Accrued			$ 0
Convertible Note, Balance			0
Debt Instrument, Converted Amount			15,000
Debt Instrument, Interest Accrued, Converted Amount			$ 939
Common Stock, shares issued			87,032,383
Convertible Prom Note #25
Date of Agreement			Sep. 4, 2015
Convertible Note			$ 19,000
Interest Rate			8.00%
Due Date			Jun. 4, 2016
Interest Accrued			$ 1,632
Convertible Note, Balance			$ 19,000
Convertible Prom Note #26
Date of Agreement					Dec. 29, 2015
Convertible Note					$ 57,378
Interest Rate					8.00%
Due Date			Jun. 23, 2017		Dec. 30, 2016
Interest Accrued			$ 51		$ 0
Convertible Note, Balance					1,609
Debt Instrument, Converted Amount					59,934
Debt Instrument, Interest Accrued, Converted Amount					$ 1,222
Common Stock, shares issued					35,927,887
Fee					Default
Fee Amount					$ 4,165
Convertible Prom Note #27
Date of Agreement			Jan. 22, 2016
Convertible Note			$ 60,500
Interest Rate			10.00%
Due Date			Oct. 22, 2016
Interest Accrued			$ 4,177
Convertible Prom Note #28
Date of Agreement			Feb. 25, 2016
Convertible Note			$ 27,500
Interest Rate			8.00%
Due Date			Feb. 25, 2017
Interest Accrued			$ 217
Convertible Note, Balance			10,755
Original Issue Discount, unamortized			836
Debt Instrument, Converted Amount			16,745
Debt Instrument, Interest Accrued, Converted Amount			$ 1,380
Common Stock, shares issued			66,500,000
Convertible Prom Note #29
Date of Agreement			Mar. 24, 2016
Convertible Note			$ 7,500
Interest Rate			8.00%
Due Date			Mar. 24, 2017
Interest Accrued			$ 312
Convertible Prom Note #34
Date of Agreement			May 25, 2016
Convertible Note			$ 30,000
Interest Rate			8.00%
Due Date			May 25, 2017
Interest Accrued			$ 842
Convertible Prom Note #30
Date of Agreement			Jun. 8, 2016
Convertible Note			$ 84,250
Interest Rate			8.00%
Due Date			Jun. 8, 2017
Interest Accrued			$ 2,105
Convertible Prom Note #32
Date of Agreement			Jun. 23, 2016
Convertible Note			$ 56,000
Interest Rate			8.00%
Due Date			Jun. 23, 2017
Interest Accrued			$ 1,215
Convertible Prom Note #35
Interest Accrued			$ 1,043

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016
Notes to Financial Statements
Change in value of derivative liability	$ (51,683)	$ (180,446)	$ (168,454)	$ (230,186)
Derivative expense		$ (142,073)		$ (335,244)
Debt Discount, Unamortized	16,005		16,005
Derivative liabilities	270,531		270,531		$ 446,912
Derivative liabilities

Equity Transactions - Schedule

Equity Transactions - Schedule of Value of Warrants (Details) - USD ($)	6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Fair value allocation of proceeds		$ 13,259
Warrant #8
Date	Jun. 9, 2015
Warrants	$ 900,000
Stock price on grant date	$ 0.02
Exercise price	$ 0.02
Expected life	5 years
Volatility	98.00%
Risk-free rate	1.74%
Calculated value	$ 13,259
Fair value allocation of proceeds	$ 13,259
Warrant #9
Date	Dec. 15, 2015
Warrants	$ 4,000,000
Stock price on grant date	$ 0.01
Exercise price	$ 0.01
Expected life	5 years
Volatility	98.00%
Risk-free rate	1.71%
Calculated value	$ 29,612
Fair value allocation of proceeds	$ 29,612

Equity Transactions - Schedul32

Equity Transactions - Schedule of Warrant Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Sep. 30, 2016	Mar. 31, 2016
Accounting Policies [Abstract]
Beginning Balance, Issued Warrants	4,930,666
Beginning Balance, Average Exercise Price	$ 0.192
Issued, Warrants
Issued, Average Exercise Price
Exercised, Warrants
Exercised, Average Exercise Price
Expired Warrants
Expired Average Exercise Price
Ending Balance, Issued Warrants	4,930,666	4,930,666
Ending Balance, Average Exercise Price	$ 0.192	$ 0.192

Equity Transactions - Schedul33

Equity Transactions - Schedule of Value of Options (Details)	6 Months Ended
	Sep. 30, 2016USD ($)$ / sharesshares
Stock Option 7
Date of Issuance	Apr. 6, 2015
Options | shares	2,040,003
Stock price on grant date	$ 0.08
Exercise price	0.08
Exercise price, modified	$ 0.01
Expected life	5 years
Volatility	99.00%
Risk-free rate	1.31%
Calculated value | $	$ 120,778
Modified value | $	$ 151,221
Stock Option 8
Date of Issuance	Jun. 9, 2015
Options | shares	1,000,000
Stock price on grant date	$ 0.02
Exercise price	0.02
Exercise price, modified	$ 0.01
Expected life	5 years
Volatility	99.00%
Risk-free rate	1.74%
Calculated value | $	$ 14,838
Modified value | $	$ 16,347
Stock Option 9
Date of Issuance	Dec. 15, 2015
Options | shares	860,000
Stock price on grant date	$ 0.01
Exercise price	0.01
Exercise price, modified	$ 0.01
Expected life	5 years
Volatility	84.00%
Risk-free rate	1.70%
Calculated value | $	$ 5,736
Modified value | $	$ 5,736

Equity Transactions - Schedul34

Equity Transactions - Schedule of Option Activity (Details) - shares	6 Months Ended	12 Months Ended
	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Accounting Policies [Abstract]
Beginning Balance, number of shares	672,533	672,533
Beginning Balance, weighted average exercise price	0.01	0.01
Options granted, number of shares	3,900,003	3,900,003	197,500	475,033
Options granted, weighted average exercise price
Options exercised, number of shares
Options exercised, weighted average exercise price
Options expired, number of shares
Options expired, weighted average exercise price
Ending Balance, number of shares		672,533	672,533
Ending Balance, weighted average exercise price		0.01	0.01

Equity Transactions (Details Na

Equity Transactions (Details Narrative)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2016USD ($)$ / sharesshares	Sep. 30, 2015USD ($)shares	Sep. 30, 2016USD ($)$ / sharesshares	Sep. 30, 2015USD ($)shares	Mar. 31, 2016$ / sharesshares	Mar. 31, 2015shares	Mar. 31, 2014shares	Mar. 31, 2013	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares	Jul. 18, 2013shares
Common Stock, Shares Authorized	4,000,000,000		4,000,000,000		4,000,000,000				375,030,000	900,000
Common Stock, Par Value | $ / shares	$ .001		$ .001		$ .001				$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000		10,000,000		10,000,000
Preferred Stock, Par Value | $ / shares	$ .001		$ .001		$ .001
Series A Preferred Stock, Designated											6,000,000
Common Stock, Issued	640,739,418		640,739,418		216,364,262
Preferred Stock, Issued	6,000,000		6,000,000		6,000,000
Common Stock, shares issued		14,690
Stock split ratio			0.01					4.1671
Options granted, number of shares				3,900,003	3,900,003	197,500	475,033
Debt Instrument, Converted Amount | $			$ 70,478	$ 308,451
Stock-based compensation | $		$ 62,301		$ 192,392
Debt Conversion #26
Date of Issuance			Apr. 1, 2015
Common Stock, shares issued			411,111
Common Stock, price per share | $ / shares			$ 0.04050
Debt Instrument, Converted Amount | $			$ 16,650
Debt Conversion #27
Date of Issuance			Apr. 6, 2015
Common Stock, shares issued			209,644
Common Stock, price per share | $ / shares			$ 0.04770
Debt Instrument, Converted Amount | $			$ 10,000
Debt Conversion #28
Date of Issuance			Apr. 8, 2015
Common Stock, shares issued			453,561
Common Stock, price per share | $ / shares			$ 0.03375
Debt Instrument, Converted Amount | $			$ 15,309
Debt Conversion #29
Date of Issuance			Apr. 9, 2015
Common Stock, shares issued			325,455
Common Stock, price per share | $ / shares			$ 0.04400
Debt Instrument, Converted Amount | $			$ 14,320
Debt Conversion #30
Date of Issuance			Apr. 14, 2015
Common Stock, shares issued			236,967
Common Stock, price per share | $ / shares			$ 0.04220
Debt Instrument, Converted Amount | $			$ 10,000
Debt Conversion #31
Date of Issuance			Apr. 16, 2015
Common Stock, shares issued			53,000
Common Stock, price per share | $ / shares			$ 0.03619
Debt Instrument, Converted Amount | $			$ 1,918
Debt Conversion #32
Date of Issuance			Apr. 21, 2015
Common Stock, shares issued			259,740
Common Stock, price per share | $ / shares			$ 0.03850
Debt Instrument, Converted Amount | $			$ 10,000
Debt Conversion #33
Date of Issuance			Apr. 29, 2015
Common Stock, shares issued			389,610
Common Stock, price per share | $ / shares			$ 0.03850
Debt Instrument, Converted Amount | $			$ 15,000
Debt Conversion #34
Date of Issuance			May 4, 2015
Common Stock, shares issued			131,464
Common Stock, price per share | $ / shares			$ 0.03866
Debt Instrument, Converted Amount | $			$ 5,083
Debt Conversion #35
Date of Issuance			May 12, 2015
Common Stock, shares issued			903,380
Common Stock, price per share | $ / shares			$ 0.03150
Debt Instrument, Converted Amount | $			$ 28,456
Debt Conversion #36
Date of Issuance			May 20, 2015
Common Stock, shares issued			947,645
Common Stock, price per share | $ / shares			$ 0.02131
Debt Instrument, Converted Amount | $			$ 20,199
Debt Conversion #37
Date of Issuance			May 20, 2015
Common Stock, shares issued			783,636
Common Stock, price per share | $ / shares			$ 0.02200
Debt Instrument, Converted Amount | $			$ 17,240
Debt Conversion #38
Date of Issuance			May 27, 2015
Common Stock, shares issued			701,801
Common Stock, price per share | $ / shares			$ 0.01933
Debt Instrument, Converted Amount | $			$ 13,568
Debt Conversion #39
Date of Issuance			May 29, 2015
Common Stock, shares issued			882,353
Common Stock, price per share | $ / shares			$ 0.01700
Debt Instrument, Converted Amount | $			$ 15,000
Debt Conversion #40
Date of Issuance			Jun. 11, 2015
Common Stock, shares issued			942,609
Common Stock, price per share | $ / shares			$ 0.01050
Debt Instrument, Converted Amount | $			$ 9,897
Debt Conversion #41
Date of Issuance			Jun. 16, 2015
Common Stock, shares issued			1,175,000
Common Stock, price per share | $ / shares			$ 0.01200
Debt Instrument, Converted Amount | $			$ 14,100
Debt Conversion #42
Date of Issuance			Jun. 16, 2015
Common Stock, shares issued			1,130,417
Common Stock, price per share | $ / shares			$ 0.01200
Debt Instrument, Converted Amount | $			$ 13,565
Debt Conversion #43
Date of Issuance			Apr. 8, 2015
Common Stock, shares issued			454,545
Common Stock, price per share | $ / shares			$ 0.04400
Debt Instrument, Converted Amount | $			$ 20,001
Debt Conversion #44
Date of Issuance			Jun. 22, 2015
Common Stock, shares issued			1,235,833
Common Stock, price per share | $ / shares			$ 0.00600
Debt Instrument, Converted Amount | $			$ 7,415
Debt Conversion #45
Date of Issuance			Jun. 22, 2015
Common Stock, shares issued			2,479,924
Common Stock, price per share | $ / shares			$ 0.00580
Debt Instrument, Converted Amount | $			$ 14,384
Debt Conversion #46
Date of Issuance			Jun. 23, 2015
Common Stock, shares issued			1,292,000
Common Stock, price per share | $ / shares			$ 0.00600
Debt Instrument, Converted Amount | $			$ 7,752
Debt Conversion #47
Date of Issuance			Sep. 16, 2015
Common Stock, shares issued			1,772,033
Common Stock, price per share | $ / shares			$ 0.00450
Debt Instrument, Converted Amount | $			$ 7,974
Debt Conversion #48
Date of Issuance			Sep. 28, 2015
Common Stock, shares issued			1,666,667
Common Stock, price per share | $ / shares			$ 0.00600
Debt Instrument, Converted Amount | $			$ 10,000
Debt Conversion #49
Date of Issuance			Sep. 29, 2015
Common Stock, shares issued			1,770,000
Common Stock, price per share | $ / shares			$ 0.00600
Debt Instrument, Converted Amount | $			$ 10,620
Debt Conversion #50
Date of Issuance			Oct. 7, 2015
Common Stock, shares issued			375,000
Common Stock, price per share | $ / shares			$ 0.0060
Debt Instrument, Converted Amount | $			$ 2,250
Debt Conversion #51
Date of Issuance			Oct. 7, 2015
Common Stock, shares issued			1,400,000
Common Stock, price per share | $ / shares			$ 0.0060
Debt Instrument, Converted Amount | $			$ 8,400
Debt Conversion #52
Date of Issuance			Oct. 19, 2015
Common Stock, shares issued			1,620,000
Common Stock, price per share | $ / shares			$ 0.0060
Debt Instrument, Converted Amount | $			$ 9,720
Debt Conversion #53
Date of Issuance			Nov. 2, 2015
Common Stock, shares issued			1,966,124
Common Stock, price per share | $ / shares			$ 0.00225
Debt Instrument, Converted Amount | $			$ 4,424
Debt Conversion #54
Date of Issuance			Nov. 23, 2015
Common Stock, shares issued			1,666,667
Common Stock, price per share | $ / shares			$ 0.0060
Debt Instrument, Converted Amount | $			$ 10,000
Debt Conversion #55
Date of Issuance			Nov. 30, 2015
Common Stock, shares issued			2,591,323
Common Stock, price per share | $ / shares			$ 0.00650
Debt Instrument, Converted Amount | $			$ 16,844
Debt Conversion #56
Date of Issuance			Dec. 9, 2015
Common Stock, shares issued			775,991
Common Stock, price per share | $ / shares			$ 0.00225
Debt Instrument, Converted Amount | $			$ 1,746
Debt Conversion #57
Date of Issuance			Dec. 17, 2015
Common Stock, shares issued			919,319
Common Stock, price per share | $ / shares			$ 0.00580
Debt Instrument, Converted Amount | $			$ 5,332
Debt Conversion #58
Date of Issuance			Dec. 28, 2015
Common Stock, shares issued			596,200
Common Stock, price per share | $ / shares			$ 0.00225
Debt Instrument, Converted Amount | $			$ 1,341
Debt Conversion #59
Date of Issuance			Dec. 28, 2015
Common Stock, shares issued			2,950,000
Common Stock, price per share | $ / shares			$ 0.00600
Debt Instrument, Converted Amount | $			$ 17,700
Debt Conversion #60
Date of Issuance			Dec. 28, 2015
Common Stock, shares issued			2,384,167
Common Stock, price per share | $ / shares			$ 0.00600
Debt Instrument, Converted Amount | $			$ 14,305
Debt Conversion #61
Date of Issuance			Dec. 28, 2015
Common Stock, shares issued			2,579,916
Common Stock, price per share | $ / shares			$ 0.00580
Debt Instrument, Converted Amount | $			$ 14,963
Debt Conversion #62
Date of Issuance			Dec. 29, 2015
Common Stock, shares issued			1,399,167
Common Stock, price per share | $ / shares			$ 0.00600
Debt Instrument, Converted Amount | $			$ 8,395
Debt Conversion #63
Date of Issuance			Dec. 29, 2015
Common Stock, shares issued			1,278,333
Common Stock, price per share | $ / shares			$ 0.00600
Debt Instrument, Converted Amount | $			$ 7,670
Debt Conversion #64
Date of Issuance			Dec. 30, 2015
Common Stock, shares issued			2,956,248
Common Stock, price per share | $ / shares			$ 0.00225
Debt Instrument, Converted Amount | $			$ 6,651
2013 Stock Option Plan Amendment
Date of Agreement			Jan. 12, 2015
Options granted, number of shares			672,533
Exercise price | $ / shares			$ 0.17
Stock-based compensation | $			$ 50,448
2013 Stock Option Plan Amdt #2
Date of Agreement			Apr. 6, 2015
Options granted, number of shares			2,712,535
Exercise price | $ / shares			$ 0.08
Stock-based compensation | $			$ 9,316
2013 Stock Option Plan Amdt #3
Date of Agreement			Aug. 4, 2015
Options granted, number of shares			3,712,535
Exercise price | $ / shares			$ 0.02
Stock-based compensation | $			$ 47,463
Debt Conversion #65
Date of Issuance			Jan. 4, 2016
Common Stock, shares issued			3,223,213
Common Stock, price per share | $ / shares			$ 0.006
Debt Instrument, Converted Amount | $			$ 19,339
Debt Conversion #66
Date of Issuance			Jan. 5, 2016
Common Stock, shares issued			3,603,227
Common Stock, price per share | $ / shares			$ 0.00225
Debt Instrument, Converted Amount | $			$ 8,107
Debt Conversion #67
Date of Issuance			Jan. 6, 2016
Common Stock, shares issued			2,678,333
Common Stock, price per share | $ / shares			$ 0.006
Debt Instrument, Converted Amount | $			$ 16,070
Debt Conversion #68
Date of Issuance			Jan. 6, 2016
Common Stock, shares issued			2,861,607
Common Stock, price per share | $ / shares			$ 0.0058
Debt Instrument, Converted Amount | $			$ 16,597
Debt Conversion #69
Date of Issuance			Feb. 16, 2016
Common Stock, shares issued			4,220,400
Common Stock, price per share | $ / shares			$ 0.00034
Debt Instrument, Converted Amount | $			$ 1,424
Debt Conversion #70
Date of Issuance			Feb. 17, 2016
Common Stock, shares issued			8,443,272
Common Stock, price per share | $ / shares			$ 0.00152
Debt Instrument, Converted Amount | $			$ 12,800
Debt Conversion #71
Date of Issuance			Feb. 23, 2016
Common Stock, shares issued			4,218,182
Common Stock, price per share | $ / shares			$ 0.0011
Debt Instrument, Converted Amount | $			$ 4,640
Debt Conversion #72
Date of Issuance			Feb. 23, 2016
Common Stock, shares issued			4,200,871
Common Stock, price per share | $ / shares			$ 0.00073
Debt Instrument, Converted Amount | $			$ 3,086
Debt Conversion #73
Date of Issuance			Feb. 24, 2016
Common Stock, shares issued			4,419,970
Common Stock, price per share | $ / shares			$ 0.00034
Debt Instrument, Converted Amount | $			$ 1,492
Debt Conversion #74
Date of Issuance			Feb. 25, 2016
Common Stock, shares issued			2,638,987
Common Stock, price per share | $ / shares			$ 0.00114
Debt Instrument, Converted Amount | $			$ 3,000
Debt Conversion #75
Date of Issuance			Feb. 25, 2016
Common Stock, shares issued			4,218,182
Common Stock, price per share | $ / shares			$ 0.0011
Debt Instrument, Converted Amount | $			$ 4,640
Debt Conversion #76
Date of Issuance			Mar. 1, 2016
Common Stock, shares issued			5,834,458
Common Stock, price per share | $ / shares			$ 0.00022
Debt Instrument, Converted Amount | $			$ 1,313
Debt Conversion #77
Date of Issuance			Mar. 2, 2016
Common Stock, shares issued			5,831,642
Common Stock, price per share | $ / shares			$ 0.00079
Debt Instrument, Converted Amount | $			$ 4,600
Debt Conversion #78
Date of Issuance			Mar. 2, 2016
Common Stock, shares issued			2,586,410
Common Stock, price per share | $ / shares			$ 0.00064
Debt Instrument, Converted Amount | $			$ 1,650
Debt Conversion #79
Date of Issuance			Mar. 2, 2016
Common Stock, shares issued			11,650,000
Common Stock, price per share | $ / shares			$ 0.0008
Debt Instrument, Converted Amount | $			$ 9,332
Debt Conversion #80
Date of Issuance			Mar. 7, 2016
Common Stock, shares issued			6,546,292
Common Stock, price per share | $ / shares			$ 0.00043
Debt Instrument, Converted Amount | $			$ 2,799
Debt Conversion #81
Date of Issuance			Mar. 11, 2016
Common Stock, shares issued			4,147,500
Common Stock, price per share | $ / shares			$ 0.00046
Debt Instrument, Converted Amount | $			$ 1,924
Debt Conversion #82
Date of Issuance			Mar. 14, 2016
Common Stock, shares issued			7,125,777
Common Stock, price per share | $ / shares			$ 0.00032
Debt Instrument, Converted Amount | $			$ 2,245
Debt Conversion #83
Date of Issuance			Mar. 15, 2016
Common Stock, shares issued			7,454,098
Common Stock, price per share | $ / shares			$ 0.00045
Debt Instrument, Converted Amount | $			$ 3,329
Debt Conversion #84
Date of Issuance			Mar. 15, 2016
Common Stock, shares issued			11,450,000
Common Stock, price per share | $ / shares			$ 0.00046
Debt Instrument, Converted Amount | $			$ 5,210
Debt Conversion #85
Date of Issuance			Mar. 22, 2016
Common Stock, shares issued			8,957,888
Common Stock, price per share | $ / shares			$ 0.00027
Debt Instrument, Converted Amount | $			$ 2,419
Debt Conversion #86
Date of Issuance			Mar. 22, 2016
Common Stock, shares issued			7,200,486
Common Stock, price per share | $ / shares			$ 0.00033
Debt Instrument, Converted Amount | $			$ 2,367
Debt Conversion #87
Date of Issuance			Mar. 22, 2016
Common Stock, shares issued			11,682,000
Common Stock, price per share | $ / shares			$ 0.00046
Debt Instrument, Converted Amount | $			$ 5,315
Debt Conversion #88
Date of Issuance			Mar. 28, 2016
Common Stock, shares issued			8,958,779
Common Stock, price per share | $ / shares			$ 0.00022
Debt Instrument, Converted Amount | $			$ 1,986
Debt Conversion #89
Date of Issuance			Apr. 1, 2016
Common Stock, shares issued			9,766,311
Common Stock, price per share | $ / shares			$ 0.000225
Debt Instrument, Converted Amount | $			$ 2,197
Debt Conversion #90
Date of Issuance			Apr. 4, 2016
Common Stock, shares issued			17,250,000
Common Stock, price per share | $ / shares			$ 0.000281
Debt Instrument, Converted Amount | $			$ 4,847
Debt Conversion #91
Date of Issuance			Apr. 7, 2016
Common Stock, shares issued			9,722,222
Common Stock, price per share | $ / shares			$ 0.000180
Debt Instrument, Converted Amount | $			$ 1,750
Debt Conversion #92
Date of Issuance			Apr. 14, 2016
Common Stock, shares issued			19,250,000
Common Stock, price per share | $ / shares			$ 0.000216
Debt Instrument, Converted Amount | $			$ 4,158
Debt Conversion #93
Date of Issuance			Apr. 15, 2016
Common Stock, shares issued			9,766,222
Common Stock, price per share | $ / shares			$ 0.000135
Debt Instrument, Converted Amount | $			$ 1,318
Debt Conversion #94
Date of Issuance			Apr. 26, 2016
Common Stock, shares issued			12,629,776
Common Stock, price per share | $ / shares			$ 0.000135
Debt Instrument, Converted Amount | $			$ 1,705
Debt Conversion #95
Date of Issuance			May 4, 2016
Common Stock, shares issued			9,718,025
Common Stock, price per share | $ / shares			$ 0.000213
Debt Instrument, Converted Amount | $			$ 2,067
Debt Conversion #96
Date of Issuance			May 31, 2016
Common Stock, shares issued			4,600,055
Common Stock, price per share | $ / shares			$ 0.000180
Debt Instrument, Converted Amount | $			$ 828
Debt Conversion #97
Date of Issuance			Jun. 2, 2016
Common Stock, shares issued			30,000,000
Common Stock, price per share | $ / shares			$ 0.000304
Debt Instrument, Converted Amount | $			$ 9,120
Debt Conversion #98
Date of Issuance			Jun. 2, 2016
Common Stock, shares issued			29,340,333
Common Stock, price per share | $ / shares			$ 0.000150
Debt Instrument, Converted Amount | $			$ 4,401
Debt Conversion #99
Date of Issuance			Jun. 14, 2016
Common Stock, shares issued			29,235,900
Common Stock, price per share | $ / shares			$ 0.000200
Debt Instrument, Converted Amount | $			$ 5,847
Debt Conversion #100
Date of Issuance			Jun. 17, 2016
Common Stock, shares issued			28,456,150
Common Stock, price per share | $ / shares			$ 0.000200
Debt Instrument, Converted Amount | $			$ 5,691
Debt Conversion #101
Date of Issuance			Jun. 29, 2017
Common Stock, shares issued			21,270,355
Common Stock, price per share | $ / shares			$ 0.000309
Debt Instrument, Converted Amount | $			$ 6,580
Debt Conversion #102
Date of Issuance			Aug. 23, 2016
Common Stock, shares issued			22,129,741
Common Stock, price per share | $ / shares			$ 0.000116
Debt Instrument, Converted Amount | $			$ 2,567
Debt Conversion #103
Date of Issuance			Aug. 29, 2016
Common Stock, shares issued			22,156,120
Common Stock, price per share | $ / shares			$ 0.000116
Debt Instrument, Converted Amount | $			$ 2,570
Debt Conversion #104
Date of Issuance			Sep. 6, 2016
Common Stock, shares issued			21,952,672
Common Stock, price per share | $ / shares			$ 0.000116
Debt Instrument, Converted Amount | $			$ 2,547
Debt Conversion #105
Date of Issuance			Sep. 20, 2016
Common Stock, shares issued			25,267,355
Common Stock, price per share | $ / shares			$ 0.000097
Debt Instrument, Converted Amount | $			$ 2,443
Debt Conversion #106
Date of Issuance			Sep. 26, 2016
Common Stock, shares issued			25,393,447
Common Stock, price per share | $ / shares			$ 0.000116
Debt Instrument, Converted Amount | $			$ 2,946
Debt Conversion #107
Date of Issuance			Sep. 28, 2016
Common Stock, shares issued			25,403,448
Common Stock, price per share | $ / shares			$ 0.000116
Debt Instrument, Converted Amount | $			$ 2,947
Debt Conversion #108
Date of Issuance			Sep. 30, 2016
Common Stock, shares issued			51,066,724
Common Stock, price per share | $ / shares			$ 0.000077
Debt Instrument, Converted Amount | $			$ 3,949
Asset Assign Agmt
Date of Agreement			Jul. 18, 2015
Common Stock, shares issued			827,670
Series A Preferred Stock, shares issued			6,000,000
Shares Issued, Value | $			$ 123,973
Sale Agmt
Shares agreed to cancel			2,625,210
Shares returned to treasury			5,002,554
Date of Agreement			Jul. 19, 2013
Warrant #1
Exercise Date			Oct. 29, 2013
Warrants | $			$ 2,500
Stock price on grant date | $ / shares			$ 30
Exercise price | $ / shares			$ 50
Expected life			1 year
Warrant #2
Exercise Date			Dec. 11, 2013
Warrants | $			$ 2,500
Stock price on grant date | $ / shares			$ 30
Exercise price | $ / shares			$ 50
Expected life			1 year
Sale of Stock #1
Issuance of common stock for cash, shares			100,381
Issuance of common stock for cash, amount | $			$ 5,405
Date of Issuance			Apr. 22, 2015
Sale of Stock #2
Issuance of common stock for cash, shares			1,542,455
Issuance of common stock for cash, amount | $			$ 10,797
Date of Issuance			Jun. 25, 2015
Sale of Stock #3
Issuance of common stock for cash, shares			1,619,423
Issuance of common stock for cash, amount | $			$ 11,336
Date of Issuance			Jul. 7, 2015
Sale of Stock #4
Issuance of common stock for cash, shares			1,439,282
Issuance of common stock for cash, amount | $			$ 10,075
Date of Issuance			Jul. 15, 2015
Sale of Stock #5
Issuance of common stock for cash, shares			1,648,840
Issuance of common stock for cash, amount | $			$ 11,542
Date of Issuance			Oct. 27, 2015

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	Sep. 30, 2016USD ($)
Accounting Policies [Abstract]
Monthly Rent	$ 2,800

Subsequent Event (Details Narra

Subsequent Event (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Sep. 06, 2013	Sep. 05, 2013
Common Stock, Shares Authorized			4,000,000,000		4,000,000,000	375,030,000	900,000
Debt Instrument, Converted Amount			$ 70,478	$ 308,451
Debt Instrument, Interest Accrued, Converted Amount			$ 5,416
Common Stock, shares issued		14,690
Debt Conversion #109
Date of Issuance	Oct. 7, 2016
Debt Instrument, Converted Amount	$ 3,035
Debt Instrument, Interest Accrued, Converted Amount	$ 346
Common Stock, shares issued	58,291,551
Debt Conversion #110
Date of Issuance	Oct. 14, 2016
Debt Instrument, Converted Amount	$ 3,030
Debt Instrument, Interest Accrued, Converted Amount	$ 350
Common Stock, shares issued	58,275,689
Debt Conversion #111
Date of Issuance	Oct. 21, 2016
Debt Instrument, Converted Amount	$ 3,033
Debt Instrument, Interest Accrued, Converted Amount	$ 355
Common Stock, shares issued	58,355,689
Debt Conversion #112
Date of Issuance	Oct. 26, 2016
Debt Instrument, Converted Amount	$ 3,025
Debt Instrument, Interest Accrued, Converted Amount	$ 358
Common Stock, shares issued	58,316,551
Debt Conversion #113
Date of Issuance	Nov. 7, 2016
Debt Instrument, Converted Amount	$ 5,015
Common Stock, shares issued	86,472,931
Convertible Prom Note #36
Date of Agreement	Oct. 20, 2016
Convertible Note	$ 58,000
Interest Rate	8.00%
Due Date	Oct. 20, 2017
Convertible Prom Note #37
Date of Agreement	Oct. 28, 2016
Convertible Note	$ 32,000
Interest Rate	8.00%
Due Date	Oct. 20, 2017